Amador Bioscience announces new chief technology officer appointment
10 January 2022 -

Amador Bioscience, a US-based global translational sciences and clinical pharmacology CRO, announced on Friday that it has named Dr Meina Liang as its new chief technology officer.

In the new role, the company said that Dr Liang is to head the strategy to establish cutting-edge bioanalysis technologies and capabilities, improving the company's global-standard services to biopharmaceutical companies.

Dr Liang has served as executive director and global head of Integrated Bioanalysis at AstraZeneca. She has held various scientist and leadership positions with increasing responsibilities at Berlex Bioscience/Schering AG, Abgenix/Amgen, and Medimmune.